Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Posaconazole (Primary) ; Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 27 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2018 Planned End Date changed from 15 Sep 2018 to 23 Nov 2018.